Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 8 702 JPY -1.46% Market Closed
Market Cap: ¥14.6T

Relative Value

The Relative Value of one Chugai Pharmaceutical Co Ltd stock under the Base Case scenario is 4 020.78 JPY. Compared to the current market price of 8 702 JPY, Chugai Pharmaceutical Co Ltd is Overvalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4 020.78 JPY
Overvaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Chugai Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
14.3T JPY 11.4 33 22.2 22.2
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57 38.2 41
US
Johnson & Johnson
NYSE:JNJ
564.7B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
287.9B CHF 4.7 30.7 12.9 15.1
US
Merck & Co Inc
NYSE:MRK
294.9B USD 4.6 15.5 10.9 12.9
CH
Novartis AG
SIX:NOVN
229.6B CHF 5.3 20.5 12.9 16.6
UK
AstraZeneca PLC
LSE:AZN
215B GBP 5.1 31.6 15.1 22.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.6
US
Pfizer Inc
NYSE:PFE
153.2B USD 2.4 15.6 7.8 10.7
FR
Sanofi SA
PAR:SAN
98.9B EUR 1.8 8.3 7.7 7.7
P/E Multiple
Earnings Growth PEG
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average P/E: 24.6
33
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57
54%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.7
29%
1.1
US
Merck & Co Inc
NYSE:MRK
15.5
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
2%
6.6
US
Pfizer Inc
NYSE:PFE
15.6
27%
0.6
FR
Sanofi SA
PAR:SAN
8.3
1%
8.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average EV/EBITDA: 44.1
22.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
US
Merck & Co Inc
NYSE:MRK
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
1%
9.2
US
Pfizer Inc
NYSE:PFE
7.8
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average EV/EBIT: 92
22.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
US
Merck & Co Inc
NYSE:MRK
12.9
8%
1.6
CH
Novartis AG
SIX:NOVN
16.6
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
10.7
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3